BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1359 related articles for article (PubMed ID: 28614836)

  • 1. Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Persson K; Barca ML; Eldholm RS; Cavallin L; Šaltytė Benth J; Selbæk G; Brækhus A; Saltvedt I; Engedal K
    Dement Geriatr Cogn Disord; 2017; 44(1-2):12-24. PubMed ID: 28614836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1997; 9 Suppl 1():191-222; discussion 247-52. PubMed ID: 9447442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs.
    Pereira JB; Cavallin L; Spulber G; Aguilar C; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Aarsland D; Lovestone S; Simmons A; Wahlund LO; Westman E;
    J Intern Med; 2014 Mar; 275(3):317-30. PubMed ID: 24118559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior Atrophy and Medial Temporal Atrophy Scores Are Associated with Different Symptoms in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Hsu JL; Lee WJ; Liao YC; Lirng JF; Wang SJ; Fuh JL
    PLoS One; 2015; 10(9):e0137121. PubMed ID: 26372372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.
    Besser LM; Litvan I; Monsell SE; Mock C; Weintraub S; Zhou XH; Kukull W
    Parkinsonism Relat Disord; 2016 Jun; 27():54-60. PubMed ID: 27089852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memory performance on the story recall test and prediction of cognitive dysfunction progression in mild cognitive impairment and Alzheimer's dementia.
    Park JH; Park H; Sohn SW; Kim S; Park KW
    Geriatr Gerontol Int; 2017 Oct; 17(10):1603-1609. PubMed ID: 27910252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.
    Korf ES; Wahlund LO; Visser PJ; Scheltens P
    Neurology; 2004 Jul; 63(1):94-100. PubMed ID: 15249617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.
    Viticchi G; Falsetti L; Buratti L; Sajeva G; Luzzi S; Bartolini M; Provinciali L; Silvestrini M
    J Alzheimers Dis; 2017; 59(1):67-75. PubMed ID: 28582863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
    Huang Y; Ito K; Billing CB; Anziano RJ;
    Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical cut-offs for visual rating scales of medial temporal, frontal and posterior atrophy in Alzheimer's disease and mild cognitive impairment.
    Ferreira D; Cavallin L; Larsson EM; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Lovestone S; Simmons A; Wahlund LO; Westman E;
    J Intern Med; 2015 Sep; 278(3):277-90. PubMed ID: 25752192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging.
    Jobst KA; Barnetson LP; Shepstone BJ
    Int Psychogeriatr; 1998 Sep; 10(3):271-302. PubMed ID: 9785148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Segmented Linear Mixed Model Analysis Reveals Association of the APOEɛ4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression.
    Chen XR; Shao Y; Sadowski MJ;
    J Alzheimers Dis; 2021; 82(3):921-937. PubMed ID: 34120907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
    Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
    Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study.
    Amieva H; Letenneur L; Dartigues JF; Rouch-Leroyer I; Sourgen C; D'Alchée-Birée F; Dib M; Barberger-Gateau P; Orgogozo JM; Fabrigoule C
    Dement Geriatr Cogn Disord; 2004; 18(1):87-93. PubMed ID: 15087583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.